Hannah Clarke

Lerapolturev will be given via intravesicular instillation to adult patients with recurrent NMIBC intended for transurethral resection of bladder tumor (TURBT) or cystectomy.

“Where we really need to see change is talking about what the patient wants, what they're worried about, and what would work best for them,” says Angela Fagerlin, PhD.

“If there is such a clear difference between what different physicians are recommending, that calls into the need for patients to be more involved in decisions,” says Angela Fagerlin, PhD.

"I think it's important to realize we're not one-dimensional, that even if we have our day job as urologists, a lot of these things affect us," says Diana Londoño, MD.

"I think what you're going to see is more of the urologic end points, the different cancers, especially prostate cancer," says Mark Moyad, MD, MPH.

"We noted in our overall population, which was about 214 women, there was a 40% discontinuation rate for Botox treatments in the office," says Katherine L. Woodburn, MD.

FACT-RNT is the first tool to measure patient reported outcomes associated with radionuclide therapy for prostate cancer.

The spray is a liquid suspension of sildenafil citrate administered orally via a spray pump.

The study considered 4 dimensions of the workplace: equal access, work-life balance, freedom from gender bias, and supportive leadership.

"Last year was a year of many changes socially within the United States. Some of those changes stirred up a lot of interest, enthusiasm, and energy for trying to direct our community toward positive change," said Manoj Monga, MD, FACS.

“If outcomes are improved for patients who take this combination — or in patients whose cancer is still progressing after being treated with hormone-based chemotherapy alone — this could be a big step forward in caring for these patients," says Moshe Ornstein, MD, MA.

"Our new study is the first post-market analysis to see how doctors are using this drug in routine practice and what their patient outcomes are,” said Soloman Woldu, MD.

In response to the findings, The American Cancer Society is launching IMPACT, an initiative aimed at reducing prostate cancer mortality.

MRI-guided SBRT reduced both acute toxicity effects and decrements in quality-of-life measures when compared with CT-guided SBRT, according to findings published in JAMA Oncology.

The environmental footprint of prostate MRI and prostate biopsy is similar to a round-trip flight from London to Paris, according to the authors.

"Even though most of the end points had been negative and found no benefit, I think there are a couple of findings that we've learned in 2022 that surprised me," says Mark A. Moyad, MD, MPH.

“Improved quality of life is the key benefit for our BPH patients," says Scott Barkin, DO.

The acceptance allows investigators to proceed with the phase 1/2a study of the intraoperative immunotherapy SURGERx with resiquimod (STM-416).

The new payment rate goes into effect January 2023 and will expand access to care for Medicare beneficiaries.

“Each unit of blood that you got during surgery was associated with about 7% higher odds of a VTE within 90 days,” says Timothy D. Lyon, MD, FACS.

Here is some of the top content on genomic testing from the past year.

"I think NAI plus BCG will be a game-changer in the community, probably more than it would be in academic medical settings," says Karim Chamie, MD.

“The number of views, viewer engagement, and the length of the video didn't have an impact on the score at all when we did our analysis,” says Daniel Bockelman.

As the year comes to a close, we revisit some of this year’s top content on malpractice in urology.

As the year comes to a close, we revisit some of this year’s top content on urologic stones.

As the year comes to a close, we revisit some of this year’s top content on next-generation imaging.

Dr. Butler discusses 2022 milestones from her practice in gender-affirming care and looks ahead to what might be on the horizon for the field in the coming year.

As the year comes to a close, we revisit some of this year’s top content on coding and reimbursement for urologic procedures.

As the year comes to a close, we revisit some of this year’s top content on benign prostatic hyperplasia.

Thomas Chi, MD, discusses 2022 milestones in stone disease and looks ahead to what might be on the horizon for the field in the coming year.